Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Transcript
Recently, the FDA approved a sixth pegfilgrastim biosimilar (Fresenius Kabi’s Stimufend) and a fourth bevacizumab biosimilar (Celltrion Healthcare’s Vegzelma), the fourth and fifth oncology biosimilars to be approved in 2022 so far. What do these approvals tell you about the current status of the oncology biosimilar space?
Alvarnas: So, the key thing about biosimilars is when the concept first came, a lot of us were thinking, "What a quaint idea." And I think there was a lot of skepticism as to whether or not this would translate into something real. I think with the new approvals, what you see is this is something real—that we have biosimilars for a significant number of meaningful oncology products.
As we see multiple biosimilars enter into a competitive race with the originator molecule, then you get to a market-competitive model that can begin to address issues of drug pricing that can foster better stewardship as well as better engagement of clinicians as they think through their purchasing contracts, their supply chains, and clinical care pathways.
So, when we look at the portfolio of all the approved biosimilars, this constitutes something real. This constitutes a path forward toward embracing deeper models of value that don't compromise patient outcomes and don't compromise patient access by ensuring that we can be both value centered and yet extraordinary stewards of great care.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.